Literature DB >> 29049128

Changing pathological diagnosis from hyperplastic polyp to sessile serrated adenoma: systematic review and meta-analysis.

Yaron Niv1.   

Abstract

The WHO published a new classification of colonic polyps in 2010, including the group of serrated polyps, which can be divided into hyperplastic polyps (HP), traditional serrated adenomas, and sessile serrated adenomas (SSA) or polyps. To assess the rate of re-diagnosis of HP to SSA and to look for possible predictors for changing the diagnosis. English Medical literature searches were performed for 'reassessment' OR 'reclassification' AND 'hyperplastic polyp' OR 'sessile serrated adenoma' till 31 January 2017. PRISMA guidelines for systematic reviews were followed. Studies that included a precise re-diagnosis of HP into SSA were included. We also looked for predictors of SSA diagnosis such as polyp location and size, patient sex and age, and synchronous advanced adenoma. Altogether, we found 220 eligible studies; 212 were excluded as they did not fulfill the inclusion criteria and we were left with eight studies including 2625 patients. The odds ratio for the number of polyps with changed pathological diagnosis from HP to SSA was 0.112 with 95% confidence interval (CI): 0.099-0.126 (P<0.0001) or 11.2%. Heterogeneity between studies was significant with Q=199.4, d.f. (Q)=9, P<0.0001, and I=95.486%. The odds ratio for changing the pathological diagnosis from HP to SSA for polyp proximal location and polyp size more than 5 mm were 4.401, 95% CI: 2.784-6.958, P<0.0001, and 8.336, 95% CI: 4.963-15.571, P<0.0001, respectively. Endoscopists and pathologists should be aware of the SSA diagnosis when finding HPs larger than 5 mm in the right colon. The diagnosis of HP in these cases should be reassessed by experienced gastrointestinal pathologists.

Entities:  

Mesh:

Year:  2017        PMID: 29049128     DOI: 10.1097/MEG.0000000000000994

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

1.  MLH1, BRAF and p53 - searching for significant markers to predict evolution towards adenocarcinoma in colonic sessile serrated lesions.

Authors:  Diana Răduţă; Octavian Marius Dincă; Gianina Viorica Micu; Luciana Nichita; Mirela Daniela Cioplea; Radu Mihai Buşcă; Raluca Ardeleanu; Radu Bogdan Mateescu; Andreea Benguş; Sabina Andrada Zurac; Cristiana Gabriela Popp; George Cristian Vlădan
Journal:  Rom J Morphol Embryol       Date:  2021 Oct-Dec       Impact factor: 0.833

2.  Colorectal Serrated Neoplasia: An Institutional 12-Year Review Highlights the Impact of a Screening Programme.

Authors:  A J McCarthy; S M O'Reilly; J Shanley; R Geraghty; E J Ryan; G Cullen; K Sheahan
Journal:  Gastroenterol Res Pract       Date:  2019-02-06       Impact factor: 2.260

3.  Automated imaging cytometry reveals dysplastic indices of colonic serrated adenomas.

Authors:  Nicholas S Samel; Qin Huang; Hiroshi Mashimo
Journal:  Future Sci OA       Date:  2020-02-21

4.  Hyperplastic polyp or sessile serrated lesion? The contribution of serial sections to reclassification.

Authors:  Diana R Jaravaza; Jonathan M Rigby
Journal:  Diagn Pathol       Date:  2020-12-09       Impact factor: 2.644

5.  Risk of colorectal cancer in first degree relatives of patients with colorectal polyps: nationwide case-control study in Sweden.

Authors:  Mingyang Song; Louise Emilsson; Bjorn Roelstraete; Jonas F Ludvigsson
Journal:  BMJ       Date:  2021-05-04

Review 6.  Artificial intelligence-assisted colonoscopy: A review of current state of practice and research.

Authors:  Mahsa Taghiakbari; Yuichi Mori; Daniel von Renteln
Journal:  World J Gastroenterol       Date:  2021-12-21       Impact factor: 5.742

7.  The prevalence of sessile serrated lesion in the colorectum and its relationship to synchronous colorectal advanced neoplasia: a systemic review and meta-analysis.

Authors:  Sz-Iuan Shiu; Hiroshi Kashida; Yoriaki Komeda
Journal:  Eur J Gastroenterol Hepatol       Date:  2021-12-01       Impact factor: 2.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.